Both the American Diabetes Association and Kidney Disease Improving Global Outcomes organization provide updated pharmacological recommendations for treating T2DM in people with CKD that include the use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Retatrutide: The Triple-Agonist That Sparked the Buzz Much of the excitement around triple-agonist peptides began with Retatrutide
GLP-1 agonists primarily act in the gut-brain axis, significantly slowing gastric emptying, promoting satiety, and consequently reducing caloric intake
The Weight Loss Connection : What makes Semaglutide particularly intriguing is its observed impact on weight
GLP-1 weight loss drugs explained Compare Mounjaro, Wegovy, Zepbound How GLP-1s work for weight loss and diabetes Side effects, safety and monitoring Cost comparisons For many patients, access to these medications is difficult due to high costs and lack of insurance coverage
This means fewer airway obstructions, more stable breathing, fewer drops in blood oxygen, and overall better sleep quality
